Furthermore, recent work demonstrated that NKp46 expression in tumor‐associated NK cells of multiple cancer types is relatively stable compared to that of other activating NK receptors in cancers, such as CD16, NKG2D, and NKp30, which can undergo proteolytic cleavage (Zingoni et al, 2016; Gauthier et al, 2019). This evidence concerns the gene KLRK1 and neoplasm.